WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Sponsor
Kessler Foundation (Other)
Overall Status
Recruiting
CT.gov ID
NCT05755061
Collaborator
(none)
32
1
2
17.9
1.8

Study Details

Study Description

Brief Summary

This study is a randomized controlled trial (RCT) that compares the effects of two different 12-month aerobic walking exercise programs on cognitive processing speed (CPS), brain MRI, and other functional outcomes in 32 adults with multiple sclerosis (MS) who are able to walk without an assistive device but demonstrate slowed CPS. Participants (N=32) will initially undergo screening via telephone, and after satisfying relevant inclusion/exclusion criteria, will provide informed consent, followed by a baseline assessment of CPS remotely via a HIPAA-compliant virtual platform (i.e., Zoom for Healthcare). This assessment will also serve as a screen for ensuring impaired CPS. Following this virtual session, participants will come into Kessler Foundation (KF) and complete a 3-hour baseline assessment (T0) that includes a relatively short battery of neuropsychological tests, a 40-minute MRI scan, tests of walking function, a short questionnaire packet, followed by cardiopulmonary exercise testing on a motor-driven treadmill. Following T0, participants will be randomly assigned into one of the two aerobic walking ET programs that are remotely-delivered and supported by KF research assistants. As the conditions are delivered and supported remotely by KF personnel, the exercise itself takes place in the home/community setting. Both conditions involve behavior coaching via Zoom for Healthcare. The experimental condition involves high-frequency, high-intensity aerobic walking ET that exceeds the published guidelines for physical activity for adults with MS (GEMS+). GEMS + initially involves 10 minutes of moderate intensity aerobic walking exercise for 3 days per week and progresses to upwards of 40 minutes of vigorous intensity aerobic walking exercise for 5 days per week by month 12. The comparison condition involves mild-to-moderate aerobic walking exercise training that approximates published guidelines (GEMS). GEMS initially involves 10 minutes of light intensity aerobic walking exercise for 2 days per week and progresses up to 30 minutes of moderate intensity aerobic walking exercise for 3 days per week. Both conditions further will be monitored based on Fitbit-measured steps per exercise session. Of note, the sample size will be enrolled using 2 overlapping waves (Wave 1 = 14 participants, Wave 2 = 18 participants), 3 months apart. Participants will return to KF at the mid-point (i.e., T6) and end-point (i.e., T12) of the 12-month intervention period to complete the same assessments as T0. The T6 and T12 outcomes will be administered by treatment-blinded research assistants.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: GEMS Plus
  • Behavioral: GEMS
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Long-Term Aerobic Walking Exercise for Restoring Cognition and Brain in People With Multiple Sclerosis
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
May 31, 2024
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: GEMS Plus

Home-based aerobic walking exercise that exceeds published physical activity guidelines for adults with MS

Behavioral: GEMS Plus
12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS

Active Comparator: GEMS

Home-based aerobic walking exercise that meets published physical activity guidelines for adults with MS

Behavioral: GEMS
12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS

Outcome Measures

Primary Outcome Measures

  1. Change in cognitive processing speed [Baseline; 6-months; 12-months]

    Participants will undertake the Symbol Digit Modalities Test as a cognitive test of cognitive processing speed as one of the primary study outcomes

  2. Change in resting-state functional connectivity [Baseline; 6-months; 12-months]

    Participants will undertake an fMRI scan to measure resting-state functional connectivity between the thalamus and other brain regions as one of the primary study outcomes

Secondary Outcome Measures

  1. Change in thalamic volume [Baseline; 6-months; 12-months]

    Participants will undertake an MRI scan to measure volume of the thalamus as a secondary study outcome

Other Outcome Measures

  1. Change in aerobic fitness [Baseline; 6-months; 12-months]

    Participants will undertake a maximal, graded exercise test on a treadmill to measure aerobic fitness

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Definite MS diagnosis

  • Relapse-free for at least 30 days

  • Have Internet access on a device larger than a smartphone

  • Willingness and ability to travel to Kessler Foundation 3 times over a 12-month period

  • Be insufficiently physically active

  • Demonstrate low fall risk based on Activities Specific Balance Confidence scores

  • Demonstrate low contraindications for exercise

  • Right handedness

  • English as a primary language

  • Demonstrate low cognitive processing speed based on a Zoom-administered Symbol Digit Modalities Test

Exclusion Criteria:
  • Acutely taken corticosteroids within 30 days of enrollment

  • Use an assistive device (i.e., cane, crutch, walker, rollator) for ambulation

  • Experienced a fall in the past 6 months

  • Have uncontrolled major depressive disorder or history of bipolar disorder or schizophrenia

  • Regularly taking medications that can affect cognition (e.g., antipsychotics, benzodiazepines)

  • Demonstrate contraindications for 3T MRI (i.e., having metal/shrapnel in the body, non-MRI compatible aneurysm clips)

  • Have severe cognitive impairment causing an inability to follow directions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kessler Foundation West Orange New Jersey United States 07052

Sponsors and Collaborators

  • Kessler Foundation

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brian Sandroff, Senior Research Scientist, Kessler Foundation
ClinicalTrials.gov Identifier:
NCT05755061
Other Study ID Numbers:
  • R-1194-22
First Posted:
Mar 6, 2023
Last Update Posted:
Mar 6, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Brian Sandroff, Senior Research Scientist, Kessler Foundation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 6, 2023